Tarsus Pharmaceuticals, Inc. (TARS)

NASDAQ: TARS · IEX Real-Time Price · USD
16.38
-0.26 (-1.56%)
At close: Aug 18, 2022 4:00 PM
16.98
+0.60 (3.66%)
After-hours: Aug 18, 2022 7:33 PM EDT
-1.56%
Market Cap 436.67M
Revenue (ttm) 17.39M
Net Income (ttm) -56.53M
Shares Out 26.66M
EPS (ttm) -2.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 52,286
Open 16.59
Previous Close 16.64
Day's Range 15.99 - 16.85
52-Week Range 10.80 - 31.00
Beta n/a
Analysts Buy
Price Target 54.06 (+230.0%)
Earnings Date Aug 8, 2022

About TARS

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lot... [Read more...]

Industry Biotechnology
IPO Date Oct 16, 2020
Employees 46
Stock Exchange NASDAQ
Ticker Symbol TARS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for TARS stock is "Buy." The 12-month stock price forecast is 54.06, which is an increase of 230.04% from the latest price.

Price Target
$54.06
(230.04% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Misses Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) delivered earnings and revenue surprises of 63.08% and 8.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements

TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; NDA submission expected this year

Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease

IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treat...

Tarsus to Present at the Jefferies 2022 Healthcare Conference

IRVINE, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatm...

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Misses Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) delivered earnings and revenue surprises of -12.64% and 90.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s...

Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements

TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; anticipated NDA submission in the second half of this year

Tarsus to Present at Bank of America 2022 Healthcare Conference

IRVINE, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatm...

Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Tarsus Pharmaceuticals, Inc. (TARS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock

IRVINE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new techno...

Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock

IRVINE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new techno...

Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of ...

TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events

Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Tre...

IRVINE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize trea...

7 Biotech Stocks to Buy With Key Catalysts for April

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies belon...

Other symbols: ALNYAPTXBMYBPMCCHRSHCM

Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements

Expecting Saturn-2 Phase 3 topline data in April 2022, the second pivotal of TP-03 for the treatment of Demodex blepharitis, and NDA submission this year

Tarsus to Present at Upcoming Investor Conferences

IRVINE, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize trea...

Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer

Dr. Trevejo brings over 20 years of clinical development experience to Tarsus as it advances development of TP-03, the first potential treatment for Demodex blepharitis, and its pipeline programs

Tarsus to Host Eye Care Leaders Webcast on Unmet Needs in Demodex Blepharitis and Potential of TP-03

Revolutionizing Treatment for Demodex Blepharitis Patients event to feature Eric Donnenfeld, M.D.; Paul Karpecki, O.D.; and Elizabeth Yeu, M.D.

Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures ...

Topline data expected in April 2022 from Saturn-2, the second Phase 3 pivotal trial of TP-03 and NDA submission remains on track for this year

Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Dir...

Dr. Yeu brings over 20 years of eye care experience, and is a highly regarded leader in clinical care and new product innovation

Tarsus to Participate at Upcoming Virtual Investor Conferences

IRVINE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treat...

Tarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021

IRVINE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treat...

Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements

On track to complete enrollment in the fourth quarter of 2021 for the Saturn-2 Phase 3, the second pivotal trial of TP-03 for the treatment of Demodex blepharitis; topline data expected in the first qua...

Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepha...

Titan real-world prevalence study data reveals that Demodex blepharitis accounts for over two-thirds of all blepharitis cases and is highly prevalent in many commonly seen patient groups

Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference

IRVINE, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treat...

Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Dir...

Ms. Crane brings over 30 years of experience in executive leadership, commercialization, and business development in the pharmaceutical and healthcare industries